<div id=toc></div>

# Table of Contents

- [q-bio.BM](#q-bio.BM) [Total: 3]
- [cs.CL](#cs.CL) [Total: 1]
- [q-bio.QM](#q-bio.QM) [Total: 1]
- [cs.AI](#cs.AI) [Total: 1]
- [cs.LG](#cs.LG) [Total: 1]


<div id='q-bio.BM'></div>

# q-bio.BM [[Back]](#toc)

### [1] [AutoBinder Agent: An MCP-Based Agent for End-to-End Protein Binder Design](https://arxiv.org/abs/2602.00019)
*Fukang Ge,Jiarui Zhu,Linjie Zhang,Haowen Xiao,Xiangcheng Bao,Fangnan Xie,Danyang Chen,Yanrui Lu,Yuting Wang,Ziqian Guan,Lin Gu,Jinhao Bi,Yingying Zhu*

Main category: q-bio.BM

TL;DR: 该论文提出了一种基于大语言模型（LLM）和模型上下文协议（MCP）的药物设计框架，整合了多项先进技术，优化了药物设计的流程。


<details>
  <summary>Details</summary>
Motivation: 现有的AI药物发现技术分散在多个平台中，导致工作流程碎片化、接口不一致且集成成本高，亟需一种统一的解决方案。

Method: 框架结合了MaSIF、Rosetta、ProteinMPNN和AlphaFold3等技术，通过LLM动态协调任务，实现从目标结构到新药生成的全流程自动化。

Result: 该系统提高了药物设计的可重复性，减少了人工成本，并确保了整个流程的可扩展性和可审计性。

Conclusion: 提出的框架通过智能协调和模块化设计，显著提升了药物设计的效率和灵活性。

Abstract: Modern AI technologies for drug discovery are distributed across heterogeneous platforms-including web applications, desktop environments, and code libraries-leading to fragmented workflows, inconsistent interfaces, and high integration overhead. We present an agentic end-to-end drug design framework that leverages a Large Language Model (LLM) in conjunction with the Model Context Protocol (MCP) to dynamically coordinate access to biochemical databases, modular toolchains, and task-specific AI models. The system integrates four state-of-the-art components: MaSIF (MaSIF-site and MaSIF-seed-search) for geometric deep learning-based identification of protein-protein interaction (PPI) sites, Rosetta for grafting protein fragments onto protein backbones to form mini proteins, ProteinMPNN for amino acid sequences redesign, and AlphaFold3 for near-experimental accuracy in complex structure prediction. Starting from a target structure, the framework supports de novo binder generation via surface analysis, scaffold grafting and pose construction, sequence optimization, and structure prediction. Additionally, by replacing rigid, script-based workflows with a protocol-driven, LLM-coordinated architecture, the framework improves reproducibility, reduces manual overhead, and ensures extensibility, portability, and auditability across the entire drug design process.

</details>


### [2] [Phase Transitions in Unsupervised Feature Selection](https://arxiv.org/abs/2602.00660)
*Jonathan Fiorentino,Michele Monti,Dimitrios Miltiadis-Vrachnos,Vittorio Del Tatto,Alessandro Laio,Gian Gaetano Tartaglia*

Main category: q-bio.BM

TL;DR: 论文提出了一种基于可微信息不平衡（DII）的无监督特征选择方法，揭示了蛋白质特征选择中的相变现象，并提供了最小特征集的原理性标准。


<details>
  <summary>Details</summary>
Motivation: 解决在数据点较少的情况下识别最小且信息丰富的特征集的挑战。

Method: 通过理论分析DII方法，将特征视为统计物理模型的坐标，研究其特征选择中的相变行为。

Result: 物理化学描述符在玻璃态和液态之间存在相变，其临界特征数与下游分类性能饱和点一致；结构描述符的相变较不明显。

Conclusion: DII为蛋白质分类提供了无监督的最小特征集选择标准，并揭示了不同特征类型的临界性机制。

Abstract: Identifying minimal and informative feature sets is a central challenge in data analysis, particularly when few data points are available. Here we present a theoretical analysis of an unsupervised feature selection pipeline based on the Differentiable Information Imbalance (DII). We consider the specific case of structural and physico-chemical features describing a set of proteins. We show that if one considers the features as coordinates of a (hypothetical) statistical physics model, this model undergoes a phase transition as a function of the number of retained features. For physico-chemical descriptors, this transition is between a glass-like phase when the features are few and a liquid-like phase. The glass-like phase exhibits bimodal order-parameter distributions and Binder cumulant minima. In contrast, for structural descriptors the transition is less sharp. Remarkably, for physico-chemical descriptors the critical number of features identified from the DII coincides with the saturation of downstream binary classification performance. These results provide a principled, unsupervised criterion for minimal feature sets in protein classification and reveal distinct mechanisms of criticality across different feature types.

</details>


### [3] [Controlling Repetition in Protein Language Models](https://arxiv.org/abs/2602.00782)
*Jiahao Zhang,Zeqing Zhang,Di Wang,Lijie Hu*

Main category: q-bio.BM

TL;DR: 该论文系统地研究了蛋白质语言模型（PLM）生成中的重复问题，并提出UCCS方法，通过受控数据集引导蛋白质生成，显著减少重复同时保持结构可靠性。


<details>
  <summary>Details</summary>
Motivation: PLMs在蛋白质结构预测和设计中表现出色，但生成时易陷入病理性重复，影响结构可靠性和功能性。

Method: 提出了量化重复的指标，并开发UCCS方法，通过构造对比集生成针对性引导向量，减少重复而不影响折叠性。

Result: UCCS在ESM-3和ProtGPT2等多个模型中优于基线方法，显著降低重复且保留AlphaFold置信度。

Conclusion: 重复控制是PLMs的核心挑战，UCCS为可靠蛋白质生成提供了新思路。

Abstract: Protein language models (PLMs) have enabled advances in structure prediction and de novo protein design, yet they frequently collapse into pathological repetition during generation. Unlike in text, where repetition merely reduces readability, in proteins it undermines structural confidence and functional viability. To unify this problem, we present the first systematic study of repetition in PLMs. We first propose quantitative metrics to characterize motif-level and homopolymer repetition and then demonstrate their negative impact on folding reliability. To address this challenge, we propose UCCS (Utility-Controlled Contrastive Steering), which steers protein generation with a constrained dataset. Instead of naively contrasting high- vs. low-repetition sequences, we construct contrastive sets that maximize differences in repetition while tightly controlling for structural utility. This disentanglement yields steering vectors that specifically target repetition without degrading foldability. Injected at inference, these vectors consistently reduce repetition without retraining or heuristic decoding. Experiments with ESM-3 and ProtGPT2 in CATH, UniRef50, and SCOP show that our method outperforms decoding penalties and other baselines, substantially lowering repetition while preserving AlphaFold confidence scores. Our results establish repetition control as a central challenge for PLMs and highlight dataset-guided steering as a principled approach for reliable protein generation.

</details>


<div id='cs.CL'></div>

# cs.CL [[Back]](#toc)

### [4] [A Large-Scale Dataset for Molecular Structure-Language Description via a Rule-Regularized Method](https://arxiv.org/abs/2602.02320)
*Feiyang Cai,Guijuan He,Yi Hu,Jingjing Wang,Joshua Luo,Tianyu Zhu,Srikanth Pilla,Gang Li,Ling Liu,Feng Luo*

Main category: cs.CL

TL;DR: 论文提出了一种全自动注释框架，用于大规模生成精确的分子结构描述，解决了人工标注成本高的问题，并通过验证证明了高精度。


<details>
  <summary>Details</summary>
Motivation: 准确对齐分子结构与自然语言是让大语言模型（LLMs）推理化学任务的关键，但人工标注成本高昂，难以构建大规模高质量数据集。

Method: 提出基于规则的化学命名法解析器，解析IUPAC名称并构建结构化XML元数据，指导LLMs生成准确的自然语言描述。

Result: 生成了约163k个分子-描述对的数据集，验证显示描述精度达98.6%。

Conclusion: 该方法为分子-语言对齐提供了可靠基础，并可扩展至更大数据集和更广的化学任务。

Abstract: Molecular function is largely determined by structure. Accurately aligning molecular structure with natural language is therefore essential for enabling large language models (LLMs) to reason about downstream chemical tasks. However, the substantial cost of human annotation makes it infeasible to construct large-scale, high-quality datasets of structure-grounded descriptions. In this work, we propose a fully automated annotation framework for generating precise molecular structure descriptions at scale. Our approach builds upon and extends a rule-based chemical nomenclature parser to interpret IUPAC names and construct enriched, structured XML metadata that explicitly encodes molecular structure. This metadata is then used to guide LLMs in producing accurate natural-language descriptions. Using this framework, we curate a large-scale dataset of approximately $163$k molecule-description pairs. A rigorous validation protocol combining LLM-based and expert human evaluation on a subset of $2,000$ molecules demonstrates a high description precision of $98.6\%$. The resulting dataset provides a reliable foundation for future molecule-language alignment, and the proposed annotation method is readily extensible to larger datasets and broader chemical tasks that rely on structural descriptions.

</details>


<div id='q-bio.QM'></div>

# q-bio.QM [[Back]](#toc)

### [5] [ProDCARL: Reinforcement Learning-Aligned Diffusion Models for De Novo Antimicrobial Peptide Design](https://arxiv.org/abs/2602.00157)
*Fang Sheng,Mohammad Noaeen,Zahra Shakeri*

Main category: q-bio.QM

TL;DR: ProDCARL通过强化学习框架生成抗菌肽（AMPs），结合扩散模型和序列属性预测器，显著提高预测活性和安全性。


<details>
  <summary>Details</summary>
Motivation: 抗菌药物耐药性威胁医疗可持续性，亟需低成本计算发现抗菌肽（AMPs）。

Method: 使用强化学习框架ProDCARL，结合扩散模型和AMP活性及毒性预测器，优化生成肽的多样性和安全性。

Result: ProDCARL将预测AMP活性均值从0.081提升至0.178，高质量候选肽占比达6.3%，并保持高多样性。

Conclusion: ProDCARL作为候选生成器缩小实验搜索空间，未来需实验验证其效果。

Abstract: Antimicrobial resistance threatens healthcare sustainability and motivates low-cost computational discovery of antimicrobial peptides (AMPs). De novo peptide generation must optimize antimicrobial activity and safety through low predicted toxicity, but likelihood-trained generators do not enforce these goals explicitly. We introduce ProDCARL, a reinforcement-learning alignment framework that couples a diffusion-based protein generator (EvoDiff OA-DM 38M) with sequence property predictors for AMP activity and peptide toxicity. We fine-tune the diffusion prior on AMP sequences to obtain a domain-aware generator. Top-k policy-gradient updates use classifier-derived rewards plus entropy regularization and early stopping to preserve diversity and reduce reward hacking. In silico experiments show ProDCARL increases the mean predicted AMP score from 0.081 after fine-tuning to 0.178. The joint high-quality hit rate reaches 6.3\% with pAMP $>$0.7 and pTox $<$0.3. ProDCARL maintains high diversity, with $1-$mean pairwise identity equal to 0.929. Qualitative analyses with AlphaFold3 and ProtBERT embeddings suggest candidates show plausible AMP-like structural and semantic characteristics. ProDCARL serves as a candidate generator that narrows experimental search space, and experimental validation remains future work.

</details>


<div id='cs.AI'></div>

# cs.AI [[Back]](#toc)

### [6] [SEISMO: Increasing Sample Efficiency in Molecular Optimization with a Trajectory-Aware LLM Agent](https://arxiv.org/abs/2602.00663)
*Fabian P. Krüger,Andrea Hunklinger,Adrian Wolny,Tim J. Adler,Igor Tetko,Santiago David Villalba*

Main category: cs.AI

TL;DR: SEISMO是一种高效的在线分子优化方法，通过利用任务描述和反馈信息，在有限的实验中实现更优的分子设计。


<details>
  <summary>Details</summary>
Motivation: 分子优化在药物发现等领域至关重要，但传统方法依赖于昂贵且耗时的实验评估，因此亟需一种样本高效的方法。

Method: SEISMO是一种基于LLM的在线优化方法，每次实验后更新模型，结合任务描述、评分和结构化反馈。

Result: 在23项任务中，SEISMO的性能比现有方法高2-3倍，50次实验内即可达到接近最优的成绩。

Conclusion: SEISMO证明了利用领域知识和结构化反馈是实现高效分子优化的关键。

Abstract: Optimizing the structure of molecules to achieve desired properties is a central bottleneck across the chemical sciences, particularly in the pharmaceutical industry where it underlies the discovery of new drugs. Since molecular property evaluation often relies on costly and rate-limited oracles, such as experimental assays, molecular optimization must be highly sample-efficient. To address this, we introduce SEISMO, an LLM agent that performs strictly online, inference-time molecular optimization, updating after every oracle call without the need for population-based or batched learning. SEISMO conditions each proposal on the full optimization trajectory, combining natural-language task descriptions with scalar scores and, when available, structured explanatory feedback. Across the Practical Molecular Optimization benchmark of 23 tasks, SEISMO achieves a 2-3 times higher area under the optimisation curve than prior methods, often reaching near-maximal task scores within 50 oracle calls. Our additional medicinal-chemistry tasks show that providing explanatory feedback further improves efficiency, demonstrating that leveraging domain knowledge and structured information is key to sample-efficient molecular optimization.

</details>


<div id='cs.LG'></div>

# cs.LG [[Back]](#toc)

### [7] [Scalable Spatio-Temporal SE(3) Diffusion for Long-Horizon Protein Dynamics](https://arxiv.org/abs/2602.02128)
*Nima Shoghi,Yuxuan Liu,Yuning Shen,Rob Brekelmans,Pan Li,Quanquan Gu*

Main category: cs.LG

TL;DR: STAR-MD是一种基于SE(3)-等变扩散模型的方法，通过联合时空注意力机制生成蛋白质轨迹，显著提升了模拟的覆盖范围、结构有效性和动态保真度。


<details>
  <summary>Details</summary>
Motivation: 分子动力学模拟在蛋白动力学研究中是金标准，但计算成本高限制了其在生物相关时间尺度上的应用。

Method: 提出STAR-MD模型，结合因果扩散变换器和联合时空注意力机制，高效捕捉复杂的时空依赖关系。

Result: 在ATLAS基准测试中表现优异，超越了现有方法，并成功生成了稳定的微秒级轨迹。

Conclusion: STAR-MD展示了在生物相关时间尺度上进行动力学模拟的巨大潜力，为蛋白功能研究提供了新工具。

Abstract: Molecular dynamics (MD) simulations remain the gold standard for studying protein dynamics, but their computational cost limits access to biologically relevant timescales. Recent generative models have shown promise in accelerating simulations, yet they struggle with long-horizon generation due to architectural constraints, error accumulation, and inadequate modeling of spatio-temporal dynamics. We present STAR-MD (Spatio-Temporal Autoregressive Rollout for Molecular Dynamics), a scalable SE(3)-equivariant diffusion model that generates physically plausible protein trajectories over microsecond timescales. Our key innovation is a causal diffusion transformer with joint spatio-temporal attention that efficiently captures complex space-time dependencies while avoiding the memory bottlenecks of existing methods. On the standard ATLAS benchmark, STAR-MD achieves state-of-the-art performance across all metrics--substantially improving conformational coverage, structural validity, and dynamic fidelity compared to previous methods. STAR-MD successfully extrapolates to generate stable microsecond-scale trajectories where baseline methods fail catastrophically, maintaining high structural quality throughout the extended rollout. Our comprehensive evaluation reveals severe limitations in current models for long-horizon generation, while demonstrating that STAR-MD's joint spatio-temporal modeling enables robust dynamics simulation at biologically relevant timescales, paving the way for accelerated exploration of protein function.

</details>
